↑ トップへ　← 戻る

Target Gene/Pathway（薬物標的遺伝子／パスウェイリスト）💬 Info on mouse-over

e.g. Sirolimus, アダリムマブ, MAP2K

ABCDEFGH I JKLMNOPQRSTUVWXYZother

90 / 286 pathways

No. KEGG PATHWAY
On map, Yellow: Drug target, Red: All disease-related		 KEGG GENES KEGG DRUG DrugBank 指定難病告示番号
1 Adipocytokine signaling pathway 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
2 Adipocytokine signaling pathway 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
3 African trypanosomiasis 💬
 2件: IL12A, IL12B 💬 D09214 💬 Ustekinumab 15件: 37, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 162, 269, 271 💬
4 African trypanosomiasis 💬
 1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
5 African trypanosomiasis 💬
 1件: IL1B 💬 D09911 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
6 African trypanosomiasis 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
7 African trypanosomiasis 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
8 AGE-RAGE signaling pathway in diabetic complications 💬
 1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
9 AGE-RAGE signaling pathway in diabetic complications 💬
 1件: IL1B 💬 D09911 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
10 AGE-RAGE signaling pathway in diabetic complications 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
11 AGE-RAGE signaling pathway in diabetic complications 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
12 Allograft rejection 💬
 2件: IL12A, IL12B 💬 D09214 💬 Ustekinumab 15件: 37, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 162, 269, 271 💬
13 Allograft rejection 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
14 Allograft rejection 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
15 Alzheimer disease 💬
 1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
16 Alzheimer disease 💬
 1件: IL1B 💬 D09911 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
17 Alzheimer disease 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 43件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
18 Alzheimer disease 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
19 Alzheimer disease 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
20 Amoebiasis 💬
 2件: IL12A, IL12B 💬 D09214 💬 Ustekinumab 15件: 37, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 162, 269, 271 💬
21 Amoebiasis 💬
 1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
22 Amoebiasis 💬
 1件: IL1B 💬 D09911 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
23 Amoebiasis 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
24 Amoebiasis 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
25 Amphetamine addiction 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 43件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
26 Amyotrophic lateral sclerosis 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 43件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
27 Amyotrophic lateral sclerosis 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
28 Amyotrophic lateral sclerosis 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
29 Antifolate resistance 💬
 1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
30 Antifolate resistance 💬
 1件: IL1B 💬 D09911 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
31 Antifolate resistance 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
32 Antifolate resistance 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
33 Antigen processing and presentation 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
34 Antigen processing and presentation 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
35 Apoptosis 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
36 Apoptosis 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
37 Asthma 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
38 Asthma 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
39 Axon guidance 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 43件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
40 B cell receptor signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 43件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
41 C-type lectin receptor signaling pathway 💬
 3件: IL12A, IL12B, IL23A 💬 D09214 💬 Ustekinumab 15件: 37, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 162, 269, 271 💬
42 C-type lectin receptor signaling pathway 💬
 1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
43 C-type lectin receptor signaling pathway 💬
 1件: IL1B 💬 D09911 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
44 C-type lectin receptor signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 43件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
45 C-type lectin receptor signaling pathway 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
46 C-type lectin receptor signaling pathway 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
47 Calcium signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 43件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
48 Cellular senescence 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 43件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
49 cGMP-PKG signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 43件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
50 Chagas disease 💬
 2件: IL12A, IL12B 💬 D09214 💬 Ustekinumab 15件: 37, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 162, 269, 271 💬
51 Chagas disease 💬
 1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
52 Chagas disease 💬
 1件: IL1B 💬 D09911 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
53 Chagas disease 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
54 Chagas disease 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
55 Coronavirus disease - COVID-19 💬
 2件: IL12A, IL12B 💬 D09214 💬 Ustekinumab 15件: 37, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 162, 269, 271 💬
56 Coronavirus disease - COVID-19 💬
 1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
57 Coronavirus disease - COVID-19 💬
 1件: IL1B 💬 D09911 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
58 Coronavirus disease - COVID-19 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
59 Coronavirus disease - COVID-19 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
60 Cytokine-cytokine receptor interaction 💬
 3件: IL12A, IL12B, IL23A 💬 D09214 💬 Ustekinumab 15件: 37, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 162, 269, 271 💬
61 Cytokine-cytokine receptor interaction 💬
 1件: IL17A 💬 D10071 💬 Ixekizumab 5件: 36, 37, 162, 269, 271 💬
62 Cytokine-cytokine receptor interaction 💬
 1件: IL17A 💬 D09967 💬 Secukinumab 7件: 13, 37, 41, 46, 160, 269, 271 💬
63 Cytokine-cytokine receptor interaction 💬
 1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
64 Cytokine-cytokine receptor interaction 💬
 1件: IL1B 💬 D09911 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
65 Cytokine-cytokine receptor interaction 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
66 Cytokine-cytokine receptor interaction 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
67 Cytosolic DNA-sensing pathway 💬
 1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
68 Cytosolic DNA-sensing pathway 💬
 1件: IL1B 💬 D09911 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
69 Dilated cardiomyopathy 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
70 Dilated cardiomyopathy 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
71 Dopaminergic synapse 💬
 3件: PPP3CA, PPP3CB, PPP3CC 💬 D00184 💬 Cyclosporine 43件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
72 Epstein-Barr virus infection 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
73 Epstein-Barr virus infection 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
74 Fc epsilon RI signaling pathway 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
75 Fc epsilon RI signaling pathway 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
76 Fluid shear stress and atherosclerosis 💬
 1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
77 Fluid shear stress and atherosclerosis 💬
 1件: IL1B 💬 D09911 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
78 Fluid shear stress and atherosclerosis 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
79 Fluid shear stress and atherosclerosis 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
80 Glucagon signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 43件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
81 Glutamatergic synapse 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 43件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
82 Graft-versus-host disease 💬
 1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
83 Graft-versus-host disease 💬
 1件: IL1B 💬 D09911 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
84 Graft-versus-host disease 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
85 Graft-versus-host disease 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
86 Hematopoietic cell lineage 💬
 1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
87 Hematopoietic cell lineage 💬
 1件: IL1B 💬 D09911 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
88 Hematopoietic cell lineage 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
89 Hematopoietic cell lineage 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
90 Hepatitis B 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
91 Hepatitis B 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
92 Hepatitis C 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
93 Hepatitis C 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
94 Herpes simplex virus 1 infection 💬
 2件: IL12A, IL12B 💬 D09214 💬 Ustekinumab 15件: 37, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 162, 269, 271 💬
95 Herpes simplex virus 1 infection 💬
 1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
96 Herpes simplex virus 1 infection 💬
 1件: IL1B 💬 D09911 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
97 Herpes simplex virus 1 infection 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
98 Herpes simplex virus 1 infection 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
99 Human cytomegalovirus infection 💬
 1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
100 Human cytomegalovirus infection 💬
 1件: IL1B 💬 D09911 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
101 Human cytomegalovirus infection 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 43件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
102 Human cytomegalovirus infection 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
103 Human cytomegalovirus infection 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
104 Human immunodeficiency virus 1 infection 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 43件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
105 Human immunodeficiency virus 1 infection 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
106 Human immunodeficiency virus 1 infection 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
107 Human papillomavirus infection 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
108 Human papillomavirus infection 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
109 Human T-cell leukemia virus 1 infection 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 43件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
110 Human T-cell leukemia virus 1 infection 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
111 Human T-cell leukemia virus 1 infection 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
112 Hypertrophic cardiomyopathy 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
113 Hypertrophic cardiomyopathy 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
114 IL-17 signaling pathway 💬
 1件: IL17A 💬 D10071 💬 Ixekizumab 5件: 36, 37, 162, 269, 271 💬
115 IL-17 signaling pathway 💬
 1件: IL17A 💬 D09967 💬 Secukinumab 7件: 13, 37, 41, 46, 160, 269, 271 💬
116 IL-17 signaling pathway 💬
 1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
117 IL-17 signaling pathway 💬
 1件: IL1B 💬 D09911 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
118 IL-17 signaling pathway 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
119 IL-17 signaling pathway 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
120 Inflammatory bowel disease 💬
 3件: IL12A, IL12B, IL23A 💬 D09214 💬 Ustekinumab 15件: 37, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 162, 269, 271 💬
121 Inflammatory bowel disease 💬
 1件: IL17A 💬 D10071 💬 Ixekizumab 5件: 36, 37, 162, 269, 271 💬
122 Inflammatory bowel disease 💬
 1件: IL17A 💬 D09967 💬 Secukinumab 7件: 13, 37, 41, 46, 160, 269, 271 💬
123 Inflammatory bowel disease 💬
 1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
124 Inflammatory bowel disease 💬
 1件: IL1B 💬 D09911 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
125 Inflammatory bowel disease 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
126 Inflammatory bowel disease 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
127 Inflammatory mediator regulation of TRP channels 💬
 1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
128 Inflammatory mediator regulation of TRP channels 💬
 1件: IL1B 💬 D09911 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
129 Influenza A 💬
 2件: IL12A, IL12B 💬 D09214 💬 Ustekinumab 15件: 37, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 162, 269, 271 💬
130 Influenza A 💬
 1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
131 Influenza A 💬
 1件: IL1B 💬 D09911 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
132 Influenza A 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
133 Influenza A 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
134 Insulin resistance 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
135 Insulin resistance 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
136 JAK-STAT signaling pathway 💬
 3件: IL12A, IL12B, IL23A 💬 D09214 💬 Ustekinumab 15件: 37, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 162, 269, 271 💬
137 Kaposi sarcoma-associated herpesvirus infection 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 43件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
138 Legionellosis 💬
 2件: IL12A, IL12B 💬 D09214 💬 Ustekinumab 15件: 37, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 162, 269, 271 💬
139 Legionellosis 💬
 1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
140 Legionellosis 💬
 1件: IL1B 💬 D09911 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
141 Legionellosis 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
142 Legionellosis 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
143 Leishmaniasis 💬
 2件: IL12A, IL12B 💬 D09214 💬 Ustekinumab 15件: 37, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 162, 269, 271 💬
144 Leishmaniasis 💬
 1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
145 Leishmaniasis 💬
 1件: IL1B 💬 D09911 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
146 Leishmaniasis 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
147 Leishmaniasis 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
148 Long-term potentiation 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 43件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
149 Malaria 💬
 1件: IL12A 💬 D09214 💬 Ustekinumab 15件: 37, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 162, 269, 271 💬
150 Malaria 💬
 1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
151 Malaria 💬
 1件: IL1B 💬 D09911 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
152 Malaria 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
153 Malaria 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
154 MAPK signaling pathway 💬
 1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
155 MAPK signaling pathway 💬
 1件: IL1B 💬 D09911 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
156 MAPK signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 43件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
157 MAPK signaling pathway 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
158 MAPK signaling pathway 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
159 Measles 💬
 2件: IL12A, IL12B 💬 D09214 💬 Ustekinumab 15件: 37, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 162, 269, 271 💬
160 Measles 💬
 1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
161 Measles 💬
 1件: IL1B 💬 D09911 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
162 mTOR signaling pathway 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
163 mTOR signaling pathway 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
164 Natural killer cell mediated cytotoxicity 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 43件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
165 Natural killer cell mediated cytotoxicity 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
166 Natural killer cell mediated cytotoxicity 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
167 Necroptosis 💬
 1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
168 Necroptosis 💬
 1件: IL1B 💬 D09911 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
169 Necroptosis 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
170 Necroptosis 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
171 Neuroactive ligand-receptor interaction 💬
 1件: NR3C1 💬 D00472 💬 Prednisolone 40件: 11, 13, 14, 25, 26, 35, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 113, 145, 162, 222, 269, 271, 296, 299, 300 💬
172 Neuroactive ligand-receptor interaction 💬
 1件: NR3C1 💬 D00980 💬 Prednisolone 40件: 11, 13, 14, 25, 26, 35, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 113, 145, 162, 222, 269, 271, 296, 299, 300 💬
173 Neuroactive ligand-receptor interaction 💬
 1件: NR3C1 💬 D00981 💬 Prednisolone 40件: 11, 13, 14, 25, 26, 35, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 113, 145, 162, 222, 269, 271, 296, 299, 300 💬
174 Neuroactive ligand-receptor interaction 💬
 1件: NR3C1 💬 D00982 💬 Prednisolone 40件: 11, 13, 14, 25, 26, 35, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 113, 145, 162, 222, 269, 271, 296, 299, 300 💬
175 Neuroactive ligand-receptor interaction 💬
 1件: NR3C1 💬 D01239 💬 Prednisolone 40件: 11, 13, 14, 25, 26, 35, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 113, 145, 162, 222, 269, 271, 296, 299, 300 💬
176 Neuroactive ligand-receptor interaction 💬
 1件: NR3C1 💬 D01998 💬 Prednisolone 40件: 11, 13, 14, 25, 26, 35, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 113, 145, 162, 222, 269, 271, 296, 299, 300 💬
177 Neuroactive ligand-receptor interaction 💬
 1件: NR3C1 💬 D02156 💬 Prednisolone 40件: 11, 13, 14, 25, 26, 35, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 113, 145, 162, 222, 269, 271, 296, 299, 300 💬
178 Neuroactive ligand-receptor interaction 💬
 1件: NR3C1 💬 D03301 💬 Prednisolone 40件: 11, 13, 14, 25, 26, 35, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 113, 145, 162, 222, 269, 271, 296, 299, 300 💬
179 NF-kappa B signaling pathway 💬
 1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
180 NF-kappa B signaling pathway 💬
 1件: IL1B 💬 D09911 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
181 NF-kappa B signaling pathway 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
182 NF-kappa B signaling pathway 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
183 NOD-like receptor signaling pathway 💬
 1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
184 NOD-like receptor signaling pathway 💬
 1件: IL1B 💬 D09911 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
185 NOD-like receptor signaling pathway 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
186 NOD-like receptor signaling pathway 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
187 Non-alcoholic fatty liver disease 💬
 1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
188 Non-alcoholic fatty liver disease 💬
 1件: IL1B 💬 D09911 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
189 Non-alcoholic fatty liver disease 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
190 Non-alcoholic fatty liver disease 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
191 Oocyte meiosis 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 43件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
192 Osteoclast differentiation 💬
 1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
193 Osteoclast differentiation 💬
 1件: IL1B 💬 D09911 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
194 Osteoclast differentiation 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 43件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
195 Osteoclast differentiation 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
196 Osteoclast differentiation 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
197 Oxytocin signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 43件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
198 Pathogenic Escherichia coli infection 💬
 1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
199 Pathogenic Escherichia coli infection 💬
 1件: IL1B 💬 D09911 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
200 Pathogenic Escherichia coli infection 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
201 Pathogenic Escherichia coli infection 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
202 Pathways in cancer 💬
 3件: IL12A, IL12B, IL23A 💬 D09214 💬 Ustekinumab 15件: 37, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 162, 269, 271 💬
203 Pathways of neurodegeneration - multiple diseases 💬
 1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
204 Pathways of neurodegeneration - multiple diseases 💬
 1件: IL1B 💬 D09911 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
205 Pathways of neurodegeneration - multiple diseases 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 43件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
206 Pathways of neurodegeneration - multiple diseases 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
207 Pathways of neurodegeneration - multiple diseases 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
208 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 43件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
209 Pertussis 💬
 3件: IL12A, IL12B, IL23A 💬 D09214 💬 Ustekinumab 15件: 37, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 162, 269, 271 💬
210 Pertussis 💬
 1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
211 Pertussis 💬
 1件: IL1B 💬 D09911 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
212 Pertussis 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
213 Pertussis 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
214 Prion disease 💬
 1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
215 Prion disease 💬
 1件: IL1B 💬 D09911 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
216 Prion disease 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 43件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
217 Prion disease 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
218 Prion disease 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
219 Proteoglycans in cancer 💬
 1件: IL12B 💬 D09214 💬 Ustekinumab 15件: 37, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 162, 269, 271 💬
220 Proteoglycans in cancer 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
221 Proteoglycans in cancer 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
222 Renin secretion 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 43件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
223 Rheumatoid arthritis 💬
 1件: IL17A 💬 D10071 💬 Ixekizumab 5件: 36, 37, 162, 269, 271 💬
224 Rheumatoid arthritis 💬
 1件: IL17A 💬 D09967 💬 Secukinumab 7件: 13, 37, 41, 46, 160, 269, 271 💬
225 Rheumatoid arthritis 💬
 1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
226 Rheumatoid arthritis 💬
 1件: IL1B 💬 D09911 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
227 Rheumatoid arthritis 💬
 1件: IL23A 💬 D09214 💬 Ustekinumab 15件: 37, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 162, 269, 271 💬
228 Rheumatoid arthritis 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
229 Rheumatoid arthritis 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
230 RIG-I-like receptor signaling pathway 💬
 2件: IL12A, IL12B 💬 D09214 💬 Ustekinumab 15件: 37, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 162, 269, 271 💬
231 RIG-I-like receptor signaling pathway 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
232 RIG-I-like receptor signaling pathway 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
233 Salmonella infection 💬
 1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
234 Salmonella infection 💬
 1件: IL1B 💬 D09911 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
235 Salmonella infection 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
236 Salmonella infection 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
237 Shigellosis 💬
 1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
238 Shigellosis 💬
 1件: IL1B 💬 D09911 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
239 Shigellosis 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
240 Shigellosis 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
241 Sphingolipid signaling pathway 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
242 Sphingolipid signaling pathway 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
243 Systemic lupus erythematosus 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
244 Systemic lupus erythematosus 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
245 T cell receptor signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 43件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
246 T cell receptor signaling pathway 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
247 T cell receptor signaling pathway 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
248 TGF-beta signaling pathway 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
249 TGF-beta signaling pathway 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
250 Th1 and Th2 cell differentiation 💬
 2件: IL12A, IL12B 💬 D09214 💬 Ustekinumab 15件: 37, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 162, 269, 271 💬
251 Th1 and Th2 cell differentiation 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 43件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
252 Th17 cell differentiation 💬
 1件: IL17A 💬 D10071 💬 Ixekizumab 5件: 36, 37, 162, 269, 271 💬
253 Th17 cell differentiation 💬
 1件: IL17A 💬 D09967 💬 Secukinumab 7件: 13, 37, 41, 46, 160, 269, 271 💬
254 Th17 cell differentiation 💬
 1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
255 Th17 cell differentiation 💬
 1件: IL1B 💬 D09911 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
256 Th17 cell differentiation 💬
 1件: IL23A 💬 D09214 💬 Ustekinumab 15件: 37, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 162, 269, 271 💬
257 Th17 cell differentiation 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 43件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
258 TNF signaling pathway 💬
 1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
259 TNF signaling pathway 💬
 1件: IL1B 💬 D09911 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
260 TNF signaling pathway 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
261 TNF signaling pathway 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
262 Toll-like receptor signaling pathway 💬
 2件: IL12A, IL12B 💬 D09214 💬 Ustekinumab 15件: 37, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 162, 269, 271 💬
263 Toll-like receptor signaling pathway 💬
 1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
264 Toll-like receptor signaling pathway 💬
 1件: IL1B 💬 D09911 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
265 Toll-like receptor signaling pathway 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
266 Toll-like receptor signaling pathway 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
267 Toxoplasmosis 💬
 2件: IL12A, IL12B 💬 D09214 💬 Ustekinumab 15件: 37, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 162, 269, 271 💬
268 Toxoplasmosis 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
269 Toxoplasmosis 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
270 Tuberculosis 💬
 3件: IL12A, IL12B, IL23A 💬 D09214 💬 Ustekinumab 15件: 37, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 162, 269, 271 💬
271 Tuberculosis 💬
 1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
272 Tuberculosis 💬
 1件: IL1B 💬 D09911 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
273 Tuberculosis 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 43件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
274 Tuberculosis 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
275 Tuberculosis 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
276 Type I diabetes mellitus 💬
 2件: IL12A, IL12B 💬 D09214 💬 Ustekinumab 15件: 37, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 162, 269, 271 💬
277 Type I diabetes mellitus 💬
 1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
278 Type I diabetes mellitus 💬
 1件: IL1B 💬 D09911 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
279 Type I diabetes mellitus 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
280 Type I diabetes mellitus 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
281 Type II diabetes mellitus 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
282 Type II diabetes mellitus 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
283 VEGF signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 43件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
284 Viral protein interaction with cytokine and cytokine receptor 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
285 Viral protein interaction with cytokine and cytokine receptor 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
286 Wnt signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 43件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
287 Yersinia infection 💬
 1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
288 Yersinia infection 💬
 1件: IL1B 💬 D09911 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
289 Yersinia infection 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
290 Yersinia infection 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬

先頭へ